Human papillomavirus-related squamous cell carcinoma
diseaseOn this page
Also known as HPV-related squamous cell carcinomahuman papilloma virus related squamous cell carcinomahuman papilloma virus-related squamous cell carcinoma
Summary
Human papillomavirus-related squamous cell carcinoma (MONDO:0020657) is a cancer and 21 clinical trials. Top therapeutic interventions include cisplatin, alpelisib, and cemiplimab. A subtype of squamous cell carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Clinical trials: 21
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | human papillomavirus-related squamous cell carcinoma |
| Mondo ID | MONDO:0020657 |
| NCIT | C27683 |
| UMLS | C1334057 |
| MedGen | 272726 |
| GARD | 0025201 |
| Is cancer (heuristic) | yes |
Also known as: HPV-related squamous cell carcinoma · human papilloma virus related squamous cell carcinoma · human papilloma virus-related squamous cell carcinoma · human papillomavirus-related squamous cell carcinoma
Disease family
This is a subtype of squamous cell carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › epithelial neoplasm › squamous cell neoplasm › squamous cell carcinoma › human papillomavirus-related squamous cell carcinoma
Related subtypes (38): bone squamous cell carcinoma, prostate squamous cell carcinoma, trachea squamous cell carcinoma, scrotum squamous cell carcinoma, skin squamous cell carcinoma, bladder squamous cell carcinoma, urethra squamous cell carcinoma, papillary squamous carcinoma, basaloid squamous cell carcinoma, pseudoglandular squamous cell carcinoma, thymus squamous cell carcinoma, ovarian squamous cell carcinoma, renal pelvis squamous cell carcinoma, ureter squamous cell carcinoma, fallopian tube squamous cell carcinoma, squamous carcinoma in situ, keratinizing squamous cell carcinoma, squamous cell lung carcinoma, esophageal squamous cell carcinoma, squamous cell breast carcinoma, adenosquamous carcinoma, cervical squamous cell carcinoma, colorectal squamous cell carcinoma, endometrial squamous cell carcinoma, gallbladder squamous cell carcinoma, gastric squamous cell carcinoma, thyroid gland squamous cell carcinoma, vaginal squamous cell carcinoma, head and neck squamous cell carcinoma, squamous cell carcinoma of the corpus uteri, squamous cell carcinoma of penis, squamous cell carcinoma of the small intestine, squamous cell carcinoma of pancreas, squamous cell carcinoma of liver and intrahepatic biliary tract, sarcomatoid squamous cell carcinoma, vulvar squamous cell carcinoma, metastatic squamous cell carcinoma, pure squamous carcinoma of the urothelial tract
Subtypes (1): human papillomavirus-related penile squamous cell carcinoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 21.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 11 |
| PHASE1/PHASE2 | 3 |
| PHASE1 | 3 |
| Not specified | 3 |
| PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT06563479 | PHASE3 | RECRUITING | A Study Comparing Personalized Radiation Therapy With Standard Radiation Therapy in People With HPV-Positive Throat Cancer |
| NCT04900623 | PHASE2 | RECRUITING | Risk-adapted Therapy in HPV+ Oropharyngeal Cancer Using Circulating Tumor (ct)HPV DNA Profile - The ReACT Study |
| NCT04988074 | PHASE2 | RECRUITING | Trial of Cemiplimab, or Cemip-Chemo Followed by Biomarker-guided Treatment for Pts w/HPV H&N Ca |
| NCT05639972 | PHASE1/PHASE2 | RECRUITING | E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers |
| NCT05686226 | PHASE2 | RECRUITING | E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers |
| NCT06505551 | PHASE1/PHASE2 | NOT_YET_RECRUITING | Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinoma |
| NCT06949800 | PHASE2 | NOT_YET_RECRUITING | CASCADE 2002: PROTECT Study, PRObiotics to TrEat Anal preCancer Trial |
| NCT03107182 | PHASE2 | COMPLETED | Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer |
| NCT03302858 | PHASE2 | UNKNOWN | A Safety and Efficacy Trial of Circumferential Anal Canal Radiofrequency Ablation for High-Grade Anal Intraepithelial Neoplasia Using the BARRX™ Anorectal Wand |
| NCT03423264 | PHASE2 | WITHDRAWN | PROGRESS Trial - Prophylactic Gabapentin for Relief of Symptoms and Improved Swallowing |
| NCT03795610 | PHASE2 | COMPLETED | IPI-549 in Patients With Locally Advanced HPV+ and HPV- Head and Neck Squamous Cell Carcinoma |
| NCT03944915 | PHASE2 | COMPLETED | De-Escalation Therapy for Human Papillomavirus Negative Disease |
| NCT04180215 | PHASE1/PHASE2 | COMPLETED | A Phase 1/2 Study in Patients With HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other Cancers |
| NCT04369937 | PHASE2 | COMPLETED | HPV-16 Vaccination and Pembrolizumab Plus Cisplatin for Intermediate Risk HPV-16-associated Head and Neck Squamous Cell Carcinoma |
| NCT05608369 | PHASE2 | WITHDRAWN | Vorinostat in Combination With Chemoradiation in Locally Advanced HPV Negative HNSCC |
| NCT05582590 | PHASE1 | NOT_YET_RECRUITING | Autologous T Cells Targeting HPV16 HPV18 & Survivin in Patients With R/R HPV-related Oropharyngeal Cancers |
| NCT05973487 | PHASE1 | ACTIVE_NOT_RECRUITING | A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors |
| NCT05472220 | PHASE1 | WITHDRAWN | Alpelisib in Combination With Carboplatin in Patients With Solid Tumors and HPV-Positive Squamous Cell Carcinoma |
| NCT03786601 | Not specified | UNKNOWN | Postmenopausal Women With Vaginal Microbiota |
| NCT03895866 | Not specified | UNKNOWN | Persistent Cervical HPV Infection With Clearance and Vaginal Microbiota |
| NCT04979000 | Not specified | COMPLETED | HPV in Sinonasal Ca: Retrospective Analysis Association of Human Papilloma Virus (HPV) Serology and Behavioral Risk Factors |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| CISPLATIN | 4 | 4 |
| ALPELISIB | 4 | 1 |
| CEMIPLIMAB | 4 | 1 |
| DIPHENHYDRAMINE | 4 | 1 |
| FAMOTIDINE | 4 | 1 |
| EGANELISIB | 2 | 1 |
| ESEPAPOGENE ZALARNAREPVEC | 2 | 1 |
| HB-201 | 1 | 1 |
| HB-202 | 1 | 1 |
| NINSIPAPOGENE SIBARNAREPVEC | 1 | 1 |
| PELTOPEPIMUT-S | 1 | 1 |
Related Atlas pages
- Drugs: Cisplatin, Alpelisib, Cemiplimab, Diphenhydramine, Famotidine